Exicure, Inc. (XCUR) Stock Price & Analysis
Exicure, Inc. (XCUR) fell 0.79% to USD 1.25 as of September 8, 2026 at 07:00 UTC, according to Nexqual real-time market data.
XCUR last closed at USD 1.25; the session ranged USD 1.23–1.28 on volume of 16,754 shares. Market capitalization is —, with a 52-week range of USD 1.05–9.48 (NCM). Source: Nexqual, September 8, 2026 at 07:00 UTC.
Key Statistics (as of September 8, 2026 at 07:00 UTC)
| Price | USD 1.25 |
|---|---|
| Change | ▼ 0.79% (down) |
| Previous Close | USD 1.25 |
| Open | USD 1.25 |
| Day Range | USD 1.23 – 1.28 |
| 52-Week Range | USD 1.05 – 9.48 |
| Volume | 16,754 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (XCUR)
Nexqual's technical model rates XCUR "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 07:00 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 37.69 (neutral) |
| vs SMA50 | Below (USD 1.58) |
| MACD | -0.1 (negative) |
From Exicure, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Food and Drug Administration (the "FDA") through the New Drug Application ("NDA") process before they may be legally marketed in the United States and are subject to similar requirements in other countries prior to marketing in those countries.
- Our Intellectual Property In our historical business, we built an intellectual property portfolio relating to our prior therapeutic candidates and our SNA technology platform.
Partnerships
- We have no collective bargaining agreement with our employees and we have not experienced any work stoppages.
- In connection with the closing of the Share Purchase Agreement, the Company and GPCR entered into a License and Collaboration Agreement to further develop and commercialize GPCR's technologies related to certain intellectual property and patents.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATXI | Avenue Therapeutics, Inc. | USD 0.54 | ▼ 4.56% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.46 | ▲ 2.93% |
| PHIO | Phio Pharmaceuticals Corp. | USD 1.08 | ▼ 4.42% |
| DRMA | Dermata Therapeutics, Inc. | USD 1.21 | ▼ 5.47% |
| QNRX | Quoin Pharmaceuticals, Ltd. | USD 7.26 | ▲ 7.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:00 UTC. This page is informational and not investment advice.